Moderate riskFDA DrugClass II

Major Pharmaceuticals levothyroxine recalled for low potency

Major Pharmaceuticals issued a recall of Levothyroxine Sodium 112 mcg tablets (Lot #N02203, expiring 09/2026) because the medication is subpotent—meaning it contains less active ingredient than labeled. Patients taking this lot may not receive the full intended dose of this thyroid replacement medication.

From the FDA notice · Read the official notice ↗

What to do

  1. Check if you have this medication (NDC 0904-6954-61, Lot #N02203).
  2. Contact your pharmacy or doctor if you have this lot—do not stop taking levothyroxine without medical guidance.
  3. Your doctor may need to verify your dose or replace your supply.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Levothyroxine Sodium Tablets, USP, 112 mcg (0.0112 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6954-61
Sold in
Nationwide
Made for
Adults (0 months and older)

This recall covers 12 products — see all of them.

Details

Units affected
N/A
Illnesses reported
None reported
Manufactured in
7000 Cardinal Pl, N/A, Dublin, OH, United States
Classification
Class II
Recall number
D-0704-2026

In the FDA's words

Description
Levothyroxine Sodium Tablets, USP, 112 mcg (0.0112 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6954-61 Subpotent Drug Lot #: N02203, Exp. Date 09/2026 Distribution: Nationwide in the USA. Affected quantity: N/A
Hazard
Subpotent Drug

12 products in this recall

The agency lists each product separately. Check every one you might have.

Related topics

PotencyDrugsSold nationwideMore from FDA Drug